News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,476 Results
Type
Article (13831)
Company Profile (101)
Press Release (252544)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88079)
Career Advice (465)
Deals (15346)
Drug Delivery (67)
Drug Development (36609)
Employer Resources (49)
FDA (6301)
Job Trends (6204)
News (150275)
Policy (14048)
Tag
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (38)
Alliances (23244)
ALS (39)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (46)
Approvals (6340)
Artificial intelligence (115)
Autoimmune disease (9)
Automation (5)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (656)
Cardiovascular disease (74)
Career advice (409)
Career pathing (12)
CAR-T (23)
Cell therapy (91)
Cervical cancer (4)
Clinical research (30981)
Collaboration (365)
Compensation (167)
Complete response letters (17)
COVID-19 (760)
CRISPR (23)
C-suite (134)
Cystic fibrosis (39)
Data (703)
Denatured (15)
Depression (10)
Diabetes (84)
Diagnostics (1327)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (69)
Drug shortages (12)
Duchenne muscular dystrophy (39)
Earnings (32377)
Editorial (14)
Employer branding (4)
Employer resources (43)
Events (37677)
Executive appointments (410)
FDA (6792)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (223)
Gene editing (41)
Generative AI (9)
Gene therapy (103)
GLP-1 (353)
Government (1306)
Grass and pollen (3)
Guidances (66)
Healthcare (3565)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (37)
Indications (14)
Infectious disease (795)
Inflammatory bowel disease (58)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (49)
Interviews (59)
IPO (5888)
IRA (29)
Job creations (2052)
Job search strategy (373)
Kidney cancer (6)
Labor market (14)
Layoffs (183)
Leadership (4)
Legal (3433)
Liver cancer (19)
Lung cancer (88)
Lymphoma (57)
Machine learning (4)
Management (16)
Manufacturing (173)
MASH (35)
Medical device (1278)
Medtech (1280)
Mergers & acquisitions (9677)
Metabolic disorders (271)
Multiple sclerosis (22)
NASH (14)
Neurodegenerative disease (26)
Neuropsychiatric disorders (8)
Neuroscience (591)
NextGen: Class of 2025 (1586)
Non-profit (595)
Now hiring (8)
Obesity (153)
Opinion (119)
Ovarian cancer (22)
Pain (58)
Pancreatic cancer (17)
Parkinson's disease (48)
Partnered (7)
Patents (130)
Patient recruitment (30)
Peanut (10)
People (29013)
Pharmaceutical (64)
Pharmacy benefit managers (12)
Phase I (8064)
Phase II (13108)
Phase III (11762)
Pipeline (544)
Policy (74)
Postmarket research (1401)
Preclinical (3238)
Press Release (25)
Prostate cancer (49)
Psychedelics (8)
Radiopharmaceuticals (121)
Rare diseases (175)
Real estate (2637)
Recruiting (17)
Regulatory (10158)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (39)
Series A (39)
Series B (15)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1630)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (38)
The Weekly (30)
Vaccines (160)
Venture capitalists (14)
Weight loss (101)
Women's health (8)
Worklife (4)
Date
Today (54)
Last 7 days (348)
Last 30 days (1060)
Last 365 days (11641)
2025 (4321)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12424)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (58)
Arkansas (3)
Asia (20174)
Australia (2618)
California (1861)
Canada (959)
China (257)
Colorado (72)
Connecticut (73)
Delaware (63)
Europe (39581)
Florida (361)
Georgia (40)
Idaho (9)
Illinois (206)
India (16)
Indiana (141)
Iowa (1)
Japan (101)
Kansas (60)
Kentucky (13)
Louisiana (2)
Maine (2)
Maryland (275)
Massachusetts (1611)
Michigan (31)
Minnesota (100)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (9)
New Hampshire (6)
New Jersey (815)
New Mexico (7)
New York (549)
North Carolina (409)
North Dakota (2)
Northern California (774)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (476)
Puerto Rico (8)
Rhode Island (10)
South America (503)
South Carolina (3)
Southern California (780)
Tennessee (36)
Texas (248)
United States (7753)
Utah (36)
Virginia (81)
Washington D.C. (32)
Washington State (127)
Wisconsin (19)
266,476 Results for "maruishi pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan
Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.
December 18, 2023
·
4 min read
Press Releases
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
May 5, 2025
·
11 min read
Business
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis PatientsApproval triggers $1.5 million milestone payment to Cara
Cara Therapeutics, Inc. today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA ® IV Injection Syringe for the treatment of pruritus in hemodialysis patients.
September 25, 2023
·
4 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Apellis Pharmaceuticals to Present at Upcoming May 2025 Investor Conferences
May 7, 2025
·
1 min read
Press Releases
X4 Pharmaceuticals Announces Reverse Stock Split
April 24, 2025
·
6 min read
Press Releases
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
May 7, 2025
·
19 min read
Press Releases
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
May 7, 2025
·
3 min read
Biotech Beach
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.
June 13, 2024
·
9 min read
1 of 26,648
Next
